| Effects of an Early Rehabilitation Program During Hospitalization in Patients With Cystic Fibrosis (NCT03100214) | Hospital de Clinicas de Porto Alegre | 2016-08-01 |
| Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study (NCT02750501) | Alcresta Therapeutics, Inc. | 2016-07-20 |
| A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult Subjects (NCT03486236) | Vertex Pharmaceuticals Incorporated | 2016-07-20 |
| Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis (NCT02718495) | Proteostasis Therapeutics, Inc. | 2016-07-19 |
| Small Circulating RNA as Molecular Markers of Lung Disease in Cystic Fibrosis (NCT02992080) | University Hospital, Montpellier | 2016-07-12 |
| The Effect of Soluble Fiber to Reduce Post-prandial Glycemic Excursion in Adults With Cystic Fibrosis (NCT02810691) | Institut de Recherches Cliniques de Montreal | 2016-07-01 |
| Orkambi Exercise Study (NCT02821130) | University of British Columbia | 2016-07-01 |
| Impact of Art Therapy on Anxiety Identified During Hospitalizations Among Children With Cystic Fibrosis Aged 8 to 13 (NCT02693431) | Nantes University Hospital | 2016-06-29 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation (NCT02725567) | Vertex Pharmaceuticals Incorporated | 2016-06-02 |
| SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis (NCT02734810) | Anthera Pharmaceuticals | 2016-06-01 |
| Virtual Reality for the Reduction of Pain During Venipuncture in Children With CF (NCT02802839) | University of Florence | 2016-06-01 |
| LBM & Lung Function in Adolescents With CF (NCT02797912) | King's College Hospital NHS Trust | 2016-06-01 |
| ICM to Evaluate the Activation of p.Phe508del-CFTR by Lumacaftor in Combination With Ivacaftor (NCT02807415) | Hannover Medical School | 2016-06-01 |
| A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation (NCT02823470) | Vertex Pharmaceuticals Incorporated | 2016-06-01 |
| 6 Minute Walk Test in Cystic Fibrosis (NCT02538575) | Assistance Publique - Hôpitaux de Paris | 2016-05-12 |
| Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase™in Patients With Cystic Fibrosis Previously Treated With Pulmozyme® (NCT02722122) | Protalix | 2016-05-01 |
| Registry Study on Cystic Fibrosis in Chinese Children (NCT02753374) | Beijing Children's Hospital | 2016-05-01 |
| Surrogate Markers of Response to New Therapies in Cystic Fibrosis Patients (NCT02965326) | Hôpital Necker-Enfants Malades | 2016-05-01 |
| Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del (NCT02797132) | Vertex Pharmaceuticals Incorporated | 2016-05-01 |
| A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation (NCT02742519) | Vertex Pharmaceuticals Incorporated | 2016-05-01 |
| Exercise and Oscillatory Positive Expiratory Pressure Therapy in Cystic Fibrosis (NCT02750722) | University of Zurich | 2016-05-01 |
| Exploratory Study on Link Between Dynamic Hyperinflation and Lung Clearance Index in Cystic Fibrosis (NCT03323983) | Centre Hospitalier Universitaire de Besancon | 2016-05-01 |
| Portal Hypertension and Systemic Endothelial Function (NCT02850692) | Hopital Foch | 2016-04-18 |
| Bioavailability and Pharmacokinetics Study of FDL169 in Healthy Subjects and Subjects With Cystic Fibrosis (NCT02767297) | Flatley Discovery Lab LLC | 2016-04-01 |
| Comparative Analysis of CO2 Monitoring Methods in Patients With CF Undergoing General Anesthesia (NCT03734822) | Nationwide Children's Hospital | 2016-03-10 |
| Assessment of Rheological Parameters of Human Sputum. (NCT02682290) | University Hospital, Grenoble | 2016-03-03 |
| Integrating Supportive Care in Cystic Fibrosis (NCT02668575) | University of Pittsburgh | 2016-03-02 |
| Backpack Carrying in Children With Cystic Fibrosis (NCT02700282) | Groupe Hospitalier du Havre | 2016-03-01 |
| A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study) (NCT02354859) | University of Washington | 2016-03-01 |
| Breath Analysis in Children by New Point-of-care Instruments (NCT03377686) | Maastricht University Medical Center | 2016-03-01 |
| Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI (NCT02848560) | Children's Hospital Medical Center, Cincinnati | 2016-03-01 |
| Outcomes in CF Patients Accessing Their Registry Health Records (NCT03434886) | Cystic Fibrosis Registry of Ireland | 2016-03-01 |
| Interactive Mobile Health Information to Enhance Patient Care at a Cystic Fibrosis Center (NCT03052231) | Landon Pediatric Foundation | 2016-03-01 |
| Sputum Validation for the Molecular Diagnosis of Respiratory Viral Infections in Cystic Fibrosis (NCT03684759) | University Hospital, Brest | 2016-02-24 |
| Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (NCT02649751) | University Hospital, Brest | 2016-02-22 |
| To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration (NCT02679729) | AstraZeneca | 2016-02-11 |
| Non Invasive Ventilation During Physical Training in Cystic Fibrosis (NCT02684552) | Karolinska University Hospital | 2016-02-01 |
| A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation (NCT02709109) | Parion Sciences | 2016-02-01 |
| Inhaled Sodium Nitrite as an Antimicrobial for Cystic Fibrosis (NCT02694393) | Schmidhofer, Mark, MD | 2016-02-01 |
| LC-MS/MS Based Method Development for the Monitoring of Antibiotic Concentrations in Sputum of Cystic Fibrosis Patients (NCT02840136) | University Ghent | 2016-02-01 |
| Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation) (NCT02707562) | Lakefront Biotherapeutics NV | 2016-02-01 |
| Real-life Follow-up of Cystic Fibrosis Patients Treated With Ivacaftor+Lumacaftor (Orkambi*) (NCT03475381) | Assistance Publique - Hôpitaux de Paris | 2016-01-22 |
| Clinical Performance of the AtbFinder® Test System for Selection of Antibiotic Therapy in Persons With Cystic Fibrosis (NCT05584982) | TGV-Dx | 2016-01-01 |
| Measures of Respiratory Health (MRH) (NCT02657837) | The Hospital for Sick Children | 2016-01-01 |
| Lipid Formulation to Increase the Bioavailability of Fatty Acids in Cystic Fibrosis (CF) Patients (NCT02646995) | Société des Produits Nestlé (SPN) | 2016-01-01 |
| Impact of Availability of Showerpatch for Patients With Intravenous Catheters (NCT02324868) | Universitaire Ziekenhuizen KU Leuven | 2016-01-01 |
| Study of GLPG1837 in Subjects With Cystic Fibrosis (S1251N Mutation) (NCT02690519) | Lakefront Biotherapeutics NV | 2016-01-01 |
| Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe CF (NCT02626182) | National Jewish Health | 2015-12-01 |
| A Study to Confirm the Long-term Safety and Effectiveness of Kalydeco in Patients With Cystic Fibrosis Who Have an R117H-CFTR Mutation, Including Pediatric Patients (NCT02722057) | Vertex Pharmaceuticals Incorporated | 2015-12-01 |
| Vitamin D and Microbiota in Cystic Fibrosis (NCT02589444) | Emory University | 2015-12-01 |
| Pharmacokinetics of FDL169 in Healthy Female Subjects (NCT02680418) | Flatley Discovery Lab LLC | 2015-12-01 |
| Hyperpolarized Xenon MRI in Cystic Fibrosis Pulmonary Exacerbations (NCT02606487) | The Hospital for Sick Children | 2015-11-01 |
| Upper and Lower Airway Colonization in Cystic Fibrosis Patients After Lung Transplantation (NCT02591524) | Hannover Medical School | 2015-11-01 |
| Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation (NCT02589236) | Nivalis Therapeutics, Inc. | 2015-11-01 |
| Dose Escalation Study of ALX-009 in Healthy Men and Cystic Fibrosis (CF) and Non-CF Bronchiectasis Patients (NCT02598999) | Alaxia SAS | 2015-11-01 |
| EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients (NCT02443688) | Celtaxsys, Inc. | 2015-10-30 |
| Association of Transcutaneous Pulse CO-oximetry With Inflammatory Lung Diseases (NCT02831348) | Boston Children's Hospital | 2015-10-01 |
| The Use of Home Oral Glucose Tolerance Test Kit in Screening Cystic Fibrosis Related Diabetes (NCT02703155) | Great Ormond Street Hospital for Children NHS Foundation Trust | 2015-10-01 |
| Pro-resolving Effect of MAG-DHA in Cystic Fibrosis (PREMDIC) (NCT02518672) | SCF Pharma | 2015-10-01 |
| Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis (NCT02465450) | Corbus Pharmaceuticals Inc. | 2015-09-29 |
| Steady-state Pharmacokinetics of Ceftazidime/Avibactam in Cystic Fibrosis (NCT02504827) | University of Southern California | 2015-09-01 |
| Hepatitis B in Cystic Fibrosis and Latent Tuberculosis Respectively (NCT02605538) | Karolinska University Hospital | 2015-09-01 |
| Controlled Ventilation CT in CF Infants (NCT01200888) | Stanford University | 2015-09-01 |
| Extension Study of Ataluren in Participants With Nonsense Mutation Cystic Fibrosis (NCT02456103) | PTC Therapeutics | 2015-08-31 |
| The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients (NCT02496780) | University of Minnesota | 2015-08-01 |
| A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation (NCT02565914) | Vertex Pharmaceuticals Incorporated | 2015-08-01 |
| Comparison of Amikacin Lung Delivery With Two Nebulizers (NCT02538588) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2015-08-01 |
| Evaluation of Nebulization and Positive Expiratory Pressure Combination (NCT02535130) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2015-08-01 |
| Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor (NCT02544451) | Vertex Pharmaceuticals Incorporated | 2015-08-01 |
| Xenon-129 and Inert Fluorinated Gas Lung MRI: Study of Healthy Volunteers and Participants With Pulmonary Disease (NCT02740868) | The Hospital for Sick Children | 2015-08-01 |
| A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation (NCT02516410) | Vertex Pharmaceuticals Incorporated | 2015-08-01 |
| (Study: Vertex IIS) Does Ivacaftor Alter Wild Type CFTR-Open Probability In The Sweat Gland Secretory Coil? (NCT02310789) | Richard Barry Moss | 2015-07-31 |
| Natural History of Noncirrhotic Portal Hypertension (NCT02417740) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2015-07-27 |
| Video Game Exercise Effectiveness of a Domiciliary Pulmonary Rehabilitation Program in Cystic Fibrosis Patients (NCT02552043) | Universidad Autonoma de Madrid | 2015-07-01 |
| 19F MRI to Evaluate Regional Ventilation in Healthy Subjects and Subjects With Cystic Fibrosis (NCT03489590) | University of North Carolina, Chapel Hill | 2015-07-01 |
| Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis (NCT02444234) | University of Southern California | 2015-07-01 |
| Initial and Chronic Methicillin Resistant Staphylococcus Aureus (MRSA) Infection in Cystic Fibrosis (CF) (NCT02684422) | University of North Carolina, Chapel Hill | 2015-07-01 |
| A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation (NCT02514473) | Vertex Pharmaceuticals Incorporated | 2015-07-01 |
| Investigating the Use of a Positive Parenting Programme to Improve Treatment Adherence in Cystic Fibrosis (NCT02501369) | Emma Wells | 2015-07-01 |
| Do More, B'More, Live Fit (NCT03109912) | Johns Hopkins University | 2015-06-17 |
| A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor (NCT02412111) | Vertex Pharmaceuticals Incorporated | 2015-06-01 |
| DPP-IV Inhibition Prior to Development of Diabetes in Patients With Cystic Fibrosis (NCT02239458) | Ram Weiss | 2015-06-01 |
| Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients (NCT02532764) | ProQR Therapeutics | 2015-06-01 |
| Glucose Tolerance in Children With Cystic Fibrosis (NCT02569229) | Christoph Saner | 2015-06-01 |
| SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis (NCT02279498) | Anthera Pharmaceuticals | 2015-06-01 |
| T Cell Memory Fuels the Innate Response in Chronic CF Lung Disease (NCT04397861) | National Jewish Health | 2015-05-06 |
| Home Monitoring to Predict Exacerbation in Cystic Fibrosis (NCT02416375) | Papworth Hospital NHS Foundation Trust | 2015-05-01 |
| Gaming Console Home-Based Exercise for Adults With Cystic Fibrosis (NCT02277860) | University of Alabama at Birmingham | 2015-05-01 |
| Using Remote Telemonitoring to Detect Early Decline in Lung Function & Streamline Clinics in Adults With Cystic Fibrosis (NCT02399241) | Sheffield Teaching Hospitals NHS Foundation Trust | 2015-05-01 |
| Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects (NCT02468908) | Savara Inc. | 2015-05-01 |
| Kinetics of YKL-40 Protein in Serum of Cystic Fibrosis Patients (NCT02305784) | Institut de Recherches Cliniques de Montreal | 2015-05-01 |
| Project UPLIFT to Reduce Anxiety and Depression in CF Patients (NCT03139266) | Virginia Commonwealth University | 2015-04-07 |
| Mechanisms for Vascular Dysfunction and Exercise Tolerance in CF (NCT02690064) | Augusta University | 2015-04-01 |
| Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study) (NCT02445053) | Vertex Pharmaceuticals Incorporated | 2015-04-01 |
| Developing and Validating a Patient-reported Outcome Instrument to Monitor Symptom Management in Pulmonary Exacerbation in CF (NCT02464267) | University of Zurich | 2015-04-01 |
| Clearing Lungs With Epithelial Sodium Channel (ENaC) Inhibition in Cystic Fibrosis (CF) (NCT02343445) | Parion Sciences | 2015-04-01 |
| Saline Hypertonic in Preschoolers + CT (NCT02950883) | University of Washington, the Collaborative Health Studies Coordinating Center | 2015-03-24 |
| Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the F508del Mutation (NCT02325362) | Assistance Publique - Hôpitaux de Paris | 2015-03-17 |
| A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation (NCT02392234) | Vertex Pharmaceuticals Incorporated | 2015-03-01 |
| Electrical Impedance Imaging of Patients With Cystic Fibrosis (NCT02524704) | Colorado State University | 2015-03-01 |